Immunosuppression and immunomodulation is a standard therapeutic strategy in the mana- gement of multiple sclerosis (MS). Advanced and rapidly progressive forms which do not respond to conventional type of therapy have a poor prognosis. Only 30% of patients confined to a wheelchair survive 10 years. High dose immunosuppressive therapy, immunoablation, with haematopoietic stem cell support may be considered to arrest further progression of intractable forms of the disease. Here we present the results of this strategy in 10 patients. Toxicity of the procedure was manageable. The primary goal was to stop progression. However, one patient improved significantly, 3 patients improved slightly their EDSS, 6 patients improved their SNRS. Improvement can occur several months after the procedure. One patient is progressing at her previous rate. In most patients, the dose of oral corticosteroids decreased significantly, further improving the quality of life.

        Key words: multiple sclerosis - treatment - immunoablation.